Bank of America Corp DE Grows Stake in Pulse Biosciences, Inc $PLSE

Bank of America Corp DE raised its holdings in shares of Pulse Biosciences, Inc (NASDAQ:PLSE - Free Report) by 8.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 866,061 shares of the company's stock after buying an additional 65,884 shares during the quarter. Bank of America Corp DE owned about 1.25% of Pulse Biosciences worth $18,698,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in PLSE. State Street Corp boosted its position in shares of Pulse Biosciences by 6.0% during the 4th quarter. State Street Corp now owns 447,067 shares of the company's stock valued at $6,138,000 after acquiring an additional 25,187 shares during the last quarter. Brooklyn Investment Group increased its position in shares of Pulse Biosciences by 330.7% in the fourth quarter. Brooklyn Investment Group now owns 130,340 shares of the company's stock worth $1,844,000 after purchasing an additional 100,081 shares during the last quarter. Portolan Capital Management LLC purchased a new stake in Pulse Biosciences in the third quarter valued at approximately $1,809,000. UBS Group AG raised its stake in Pulse Biosciences by 53.4% in the third quarter. UBS Group AG now owns 76,856 shares of the company's stock valued at $1,360,000 after purchasing an additional 26,739 shares in the last quarter. Finally, Panoramic Capital LLC lifted its position in Pulse Biosciences by 36.6% during the third quarter. Panoramic Capital LLC now owns 35,996 shares of the company's stock valued at $637,000 after purchasing an additional 9,635 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Price Performance

Shares of PLSE stock opened at $47.02 on Thursday. The stock has a market capitalization of $3.25 billion, a PE ratio of -39.85 and a beta of 1.61. Pulse Biosciences, Inc has a 1-year low of $12.56 and a 1-year high of $48.84. The business has a 50-day moving average of $32.14 and a 200 day moving average of $25.43.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The company had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.53 million. Analysts anticipate that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on PLSE. Canaccord Genuity Group increased their price target on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Needham & Company LLC initiated coverage on shares of Pulse Biosciences in a report on Monday. They set a "buy" rating and a $58.00 price objective for the company. Oppenheimer reiterated an "outperform" rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Weiss Ratings reissued a "sell (d-)" rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Finally, Mizuho set a $45.00 price target on Pulse Biosciences in a research report on Monday, August 10th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $45.25.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source